INTRODUCTION
The plasminogen activators tPA and uPA are serine proteases catalysing the conversion of the zymogen plasminogen to the active serine protease plasmin which can degrade fibrin and other extracellular proteins. The activities of tPA and uPA are regulated by plasminogen activator inhibitor-1 (PAI-1) (for reviews, see [1, 2] ). In tissues, plasminogen activation is concentrated on cell surfaces where the GPI-anchored uPA receptor (uPAR) recruits uPA (for a review, see [3] ). Plasminogen activation is implicated in the spread of cancers in which uPA-catalysed plasmin generation in tumours leads to degradation of basement membranes, thereby supporting the cancer cell invasiveness. It was therefore initially surprising that a high tumour level of PAI-1 is an even better marker for a poor prognosis. The functions of PAI-1 in the spread of malignant tumours are not completely known, but one important aspect seems to be a proangiogenic effect of PAI-1 (for a review, see [2] ).
PAI-1 belongs to the serpin family of protease inhibitors (for a review, see [4] ). During reaction of a serpin with its target serine protease, the P1-P1' bond in the reactive centre loop (RCL) of the serpin is cleaved and the protease becomes attached to the serpin by an ester bond between the active site Ser and the P1 residue [5] . At this point, the N-terminal part of the RCL is inserted as β-strand 4A (s4A) in the serpin (Figure 1 ). The protease is thereby pulled to the opposite pole of the serpin, its active site distorted, hydrolysis of the ester bond prevented, resulting in a trapped covalent serpin-protease complex [6, 7] . Insertion of the RCL changes the serpin from a metastable, stressed (S) conformation to a more stable, relaxed (R) conformation and the released energy is believed to fuel protease distortion [8, 9] .
For some serpins, including PAI-1, the N-terminal part of the RCL can be inserted without P1-P1' bond cleavage, resulting in formation of the latent state [10] . The S to R transition includes conformational changes around α-helix D (hD) and hE which serve as a flexible joint region when the small and the large serpin fragments slide apart to allow RCL insertion [11] ( Figure 1 ). In PAI-1, a hydrophobic cavity in this region serves as the binding site for multiple PAI-1-neutralising compounds and is rearranged during the S to R transition [12] [13] [14] . Also, a high-affinty binding site for vitronectin exists in the flexible joint region of the S-form of 6 Enghild (Department of Molecular Biology, University of Aarhus, Denmark). Antithrombin III was a gift from the late Professor S. Magnusson (Department of Molecular Biology, University of Aarhus, Denmark) Receptor-associated protein (RAP) was prepared as described previously [23] . Antibodies were described previously as follows: Monoclonal anti-PAI-1 antibodies Mab-1, Mab-2, Mab-3, Mab-5, Mab-6, and Mab-7 [24] [25] [26] ; polyclonal rabbit anti-PAI-1 antibody [27] ; and monoclonal anti-uPA Mab-2 [28] .
Receptors
A stop codon succeeding the codon for amino acid 772 was introduced into the human VLDLR type-I cDNA [29] . This cDNA, encoding soluble VLDLR (residues 1-772) without the cytosolic domain and transmembrane region, was then cloned into the plasmid pcDNA3.1(-) (Invitrogen) and authenticated by DNA sequencing. E. coli DH5α cells (Invitrogen) were used for plasmid propagation and transient transfection of HEK 293T cells was carried out by standard methods [30] . Soluble VLDLR was purified from serum-free conditioned medium from transfected cells by affinity chromatography at 4 °C on a 5 mL RAP-coupled Sepharose column. HBS supplemented with 2 mM CaCl 2 and 1 mM MgCl 2 was used for equilibration and washing of the column while elution was carried out with 0.1 M CH 3 COOH, pH 3.5, 0.5 M NaCl, 10 mM EDTA. Fractions were neutralised immediately with 0.1 volume 1 M Tris, pH 9, 25 mM CaCl 2 and those containing soluble VLDLR selected based on 125 I-RAP ligand blots [31] . Purified soluble VLDLR was concentrated with a Centriplus YM-10 spin column, dialysed into PBS, and stored at -80 °C.
Full length LRP-1A purified from human placentas was a kind gift from J. Gliemann [32] .
Isolation of PAI-1-binding peptides from a phage-displayed peptide library
Phage displayed random peptide libraries in the formats X 7 , CX 7 C, CX 10 C and CX 3 CX 3 CX 3 C (C, cysteine; X, any residue) were obtained from Erkki Koivunen, Division of Biochemistry, University of Helsinki, Finland [33] . Selection of PAI-1 binding peptides was performed using standard procedures [34] . Phage and PAI-1 expressed from HT-1080 cells (100 nM) were incubated in MBS (140 mM NaCl, 10 mM MES, pH 6) supplemented with 1% bovine serum albumin (BSA) and 5% glycerol (MBS-BG) for 1 h and formed phage-PAI-1 complexes were captured on polystyrene-adsorbed monoclonal anti-PAI-1 antibody Mab-7
( Phage was prepared from 16 individual clones eluted from each of the panning rounds 2 to 5 and tested for PAI-1 binding in ELISA format 1 (see below). PAI-1-binding peptides were identified by sequencing the corresponding phage [25] . Concentrated phage (~10 12 cfu/mL) was prepared by precipitation with NaCl and PEG 6000 [34] , followed by resuspension in MBS supplemented with 10% glycerol and 0.02% NaN 3 .
The binding of the phage to PAI-1 from HT-1080 cells was compared by incubating ~10 9 cfu/mL phage with PAI-1 (300 to 0.2 nM) followed by detection of any formed phage-PAI-1 complexes in ELISA format 1. The EC 50 value for each phage was determined as the PAI-1 concentration required for half-maximal saturation in this ELISA.
NMR Structure determination
NMR spectra were recorded on a Bruker NMR spectrometer operating at 600.13
MHz at 10 °C. The sample was 1 mM NH 2 -DVPCFGWCQDA-COOH in 20% (v/v) D 6 -DMSO, 10 mM NaH 2 PO 4 , and 75 μM NaN 3 in H 2 O, pH 4.7. COSY [35] , and NOESY spectra (400 ms) [36] were recorded. Water was suppressed using pre-saturation. NMR data was processed using NMRPipe [37] . Complete assignment of 1 H chemical shifts [38] was done using NMRVIEW [39] (Table S1 ). A total of 1000 structures were calculated using the "Crystallographic and NMR system" (CNS) program package version 1.1 [40] using a total of 51 NOE derived distance constraints (Table S2 ). The obtained structures were visualised using the program MOLMOL [41] . Based on the orientations of the aromatic Phe  5 and Trp   7 side chains, 88 of the 100 structures with the lowest energy could be divided into 9 distinct conformational groups.
Molecular modelling
The molecular modelling studies were carried out using the A rigid body minimization was included for optimal placement of the peptide inside the cavity (10 iterations, final minimization with 100 iterations). The generated peptide conformations were clustered using the complete linkage option and 3 ligand-protein structures for each of the 9 original paionin-1 conformations were saved. In these poses, the peptide structure was fully minimized (max. 10,000 iterations using the Cerius2 smart minimizer). The poses were selected based on the scoring functions calculated in Cerius2 and visual inspection ensuring that both termini of paionin-1 were protruding from the surface of PAI-1. Remaining strain introduced during the molecular docking was relieved by partial minimisation using NAMD [44] and the CHARMM27 force field [45] . Protein residues within 3.0 Å of docked paionin-1 in the structure of latent PAI-1 as well as paionin-1 itself were allowed to move during the final minimization.
Determination of the critical micelle concentration
The conductivity at each peptide concentration was measured on a standard conductivity-meter by titrating it into pure water adjusted to pH 7.4 with NaOH. As a reference, a profile for titrating the same volumes of buffer without peptide was determined and subtracted from the peptide profile. The change in hydrodynamic size as a determinant of critical micelle concentration was determined by photon correlation spectroscopy using a Zetasizer Nano ZS (Malvern Instruments). The analysis was performed at 25 °C in HBS while titrating in biotin-paionin-1. Sampling time and analysis was set to automatic.
Analysis of paionin-1 binding by ELISA
In the four ELISA formats described below, all incubations were performed with 100 µL per well in MaxiSorp 96-well plates (Nunc) coated with 250 ng antibody in 0.1 M Na 2 CO 3 , pH 9.6 (formats 1, 2 and 4), or in Ni-NTA HisSorb Strips (Qiagen) (format 3).
Unless stated otherwise, PBS supplemented with 2% BSA was used for blocking the wells In ELISA format 2, wells were coated with a polyclonal rabbit-anti PAI-1 antibody.
Samples of mostly active PAI-1 variants (100 nM) were prepared and split into three aliquots which were incubated 16 h at 0 °C to preserve activity; incubated 16 h at 37 °C to obtain latent material; or reacted with a 2-fold excess of uPA for 30 min at room temperature and then stored at 0 °C for 16 h. Three-fold dilution series of the different forms of PAI-1 variants were incubated in the wells and after washing, paionin-1 phage clone B (~10 9 cfu/mL) was allowed to bind PAI-1. The wells were washed and bound phage detected.
In ELISA format 3, 50 nM His 6 -tagged PAI-1 variants were incubated 16 h at 37 °C to obtain latent material. These samples and samples of active PAI-1 were immobilised in HisSorb wells. After washing, paionin-1 phage clone B (10 9 cfu/mL) was allowed to bind PAI-1. The wells were washed and bound phage was detected as described above. To ensure that equal amounts of the individual PAI-1 variants were bound to the wells, a parallel ELISA was performed with 1 µg/mL polyclonal rabbit-anti-PAI-1 antibody instead of phage and with HRP-conjugated swine-anti-rabbit serum (DAKO, diluted 2,000-fold) instead of anti-M13
antibody.
In ELISA format 4, wells were coated with a polyclonal rabbit-anti PAI-1 antibody followed by incubation with recombinant PAI-1 variants (5 nM) and 0.3 µM biotin-paionin-1 peptide. After washing the wells, captured PAI-1-peptide complexes were detected with HRPconjugated avidin (DAKO, diluted 10,000-fold) and a peroxidase reaction as described above.
Equal loading of PAI-1 was assured by a parallel ELISA with 1 µg/mL monoclonal anti-PAI-1 Mab-1 antibody instead of peptide and with HRP-conjugated rabbit-anti-mouse serum (DAKO, diluted 2,000-fold) instead of HRP-conjugated avidin. After the incubation, the supernantants were removed for γ-counting and the wells washed.
Analysis of paionin-1 binding by surface plasmon resonance (SPR)
Bound ligand was released from the wells with 10% SDS and taken for γ-counting. Ligand binding was expressed as bound divided by total ligand and corrected for non-specific binding, i.e. the radioactivity recovered from wells without receptor. These data were then corrected for small variations in the actual relative amount of complex, by the use of the binding of complex to parallel wells coated with 20 µg/mL anti-PAI-1 Mab-2 antibody.
Receptor-mediated ligand degradation
U937 cells were washed 3 times with serum-free medium supplemented with 0.5% BSA and incubated for 45 min at 37 °C in 0.5 mL of the same buffer with 10 pM 125 I-labelled ligand and a cell density of 10 × 10 6 cells/mL. The cultures were then made 7% with respect to trichloroacetic acid and centrifuged. Supernatant and pellets were γ-counted separately.
Ligand degradation was defined as non-trichloroacetic acid precipitable radioactivity divided by the total amount of added radioactivity. The degradation in incubations without cells were scored as nonspecific degradation and subtracted from all other data [31, 46] . Under the conditions used degradation proceeded linearly with time.
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RESULTS AND DISCUSSION
Selection of PAI-1 binding peptides from phage-displayed peptide libraries
A mixture of four different phage-displayed random peptide repertoires was panned against PAI-1 in order to isolate specific PAI-1-binders. As bait, we used human glycosylated PAI-1 from HT-1080 fibrosarcoma cells. To avoid denaturation of PAI-1 by its immobilisation on plastic [25, 47] , phage was allowed to bind PAI-1 in solution before capture of phage-PAI-1 complexes on immobilised monoclonal anti-PAI-1 antibody.
Enrichment of antibody-binding peptides was avoided by using alternating antibodies, i.e.
Mab-7, -5 or -3, for capture. The output:input ratio of phage increased 100-fold from round 1 to round 5 (data not shown). Individual phage from selection rounds 2 to 5 were tested for PAI-1-binding in a sandwich ELISA and sequencing of positives identified a short disulphideconstrained loop CFG(W/Y/F)C as a well-defined consensus-motif (Table 1) . To compare the isolated phage, their EC 50 for PAI-1 binding was determined and revealed no gross variation among the different peptides, advocating that the consensus-residues are the major determinants of binding (Table 1) . Importantly, these EC 50 values do not reflect the actual affinity between the displayed peptide and PAI-1 since each phage carry more than one copy of the peptide thus causing avidity effects, i.e. an apparently tighter phage-PAI-1 binding than warranted by the affinity in the 1:1 peptide-PAI-1 complex. In the following, a peptide with the sequence DVPCFGWCQDA will be referred to as paionin-1. This sequence is a chimera of clones A and B devoid of the flanking cysteines (Table 1) . That this second disulfide was dispensable for binding could be inferred from the isolation of clone G (ILCFGMC, see Table   1 ).
The paionin-1 peptide inhibited the PAI-1-binding of phage clone B with an IC 50 of 1.8 ± 0.8 µM (n=3) while a linear version with the two cysteines replaced by serines had no effect on binding (Figure 2A ). This advocates that the constraint imposed by the disulphide locks (anti-uPA Mab-2) had no effect ( Figure 2B ). Considering the epitopes for the employed antibodies and vitronectin, these data are consistent with a binding site for paionin-1close to hF of PAI-1. PAI-1-binding of phage was also inhibited by the organochemical PAI-1 neutralizers XR-5118 and bis-ANS, which are known to bind hydrophobic surfaces in the flexible joint region of PAI-1 [13, 48, 49] , and by heparin which binds basic residues in and around hD [50] (Figure 2A ). In summary, these competition experiments suggested a hydrophobic binding site for the disulphide-constrained CFGWC loop of paionin-1 in the flexible joint region of PAI-1.
Solution structure of paionin-1
Expecting that the main chain and to some extent the side chains of a five residue ring such as the CFGWC motif of paionin-1 would be stabilised by inherent strain we analysed paionin-1 by liquid state NMR spectroscopy. The peptide proton signals were well resolved in the resulting spectra and all except for those of the N-terminal amide were assigned (Table   S1 ). A total of 51 NOEs could be identified and used in the structure calculations (Table S2 ).
In the 100 calculated structures with the lowest energy, the main-chain of the CFGWC ring was well conserved with a low RMSD (1.08 ± 0.51 Å). The structure of the residues flanking the CFGWC ring is less well-defined as the only forces directing their conformation seem to be steric repulsion by other residues which leads to the predominantly orthogonal orientation of both termini relative to the planar CFGWC ring ( Figure 3A ). As expected from the primary structure, paionin-1 is polarised with respect to hydrophobicity since the two hydrophobic side chains of the Phe 5 and Trp 7 points in the opposite direction of the more polar segments flanking the ring.
By visual inspection we found that in 88 of the 100 structures the Phe 5 and Trp 7 side chains adapted one of nine different conformations relative to the CFGWC ring, one example depicted in Figure 3A . Accordingly, these 88 structures were divided into nine conformational groups based on the orientation of these two side chains (Table 2 and Figure 3B ). Since there was no correlation between the calculated energy and the grouping of the 88 structures we conclude that from an energetic perspective each of the conformations is equally likely to occur.
Molecular modelling of the paionin-1 interaction with PAI-1
The X-ray crystal structures of highest resolution of active PAI-1 carrying the stabilising mutations N152H/K156T/Q321L/M356I [43] and latent PAI-1 (Stein, P.E. and
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Baek, K., unpublished work) were searched for cavities capable of accommodating paionin-1.
In both structures, the calculations revealed only one cavity with a total volume compatible with paionin-1 binding. The cavity was positioned in the flexible joint region between hD, hE and s2A, thus overlapping with that identified by Elliot et al. (cavity 2 in [14] ). The total volume of the cavity was almost conserved between active PAI-1 14-1B (~350 Å 3 ) and latent PAI-1 (~290 Å 3 ), but the cavity in active PAI-1 14-1B consists of numerous narrow extensions from the centre of the cavity, whereas the cavity in the latent form consists almost entirely of one single moiety.
We next used in silico docking procedures to evaluate whether paionin-1 would fit into the identified cavities in active PAI-1 14-1B and latent PAI-1. The lowest energy structure of paionin-1 from each of the 9 conformational groups was used as the ligand for docking and three converged solutions were obtained from each of the peptide structures. That the peptides containing the CFGWC motif listed in Table 1 can bind PAI-1 in the context of a phage, in which the displayed peptide sequence is preceded by Ala-Asp-Gly-Ala and followed by the phage coat protein [34] , allowed us to disqualify docking solutions in which the termini of paionin-1 do not protrude from the surface of PAI-1. Accordingly, only three solutions were acceptable (one solution shown in Figure 4A ), all with the entire CFGWC ring of paioinin-1 buried deep into the cavity of latent PAI-1. Importantly, since the ligand docking algorithm mimics structural flexibility through the use of soft potentials, the docked structures contained atomic overlaps between paionin-1 and PAI-1. Nonetheless, the cavity search and subsequent docking routines unequivocally pointed to the flexible joint region as the binding site for paionin-1 and suggested a preferential binding to the latent conformation of PAI-1.
Solubility properties of biotin-paionin-1
Handling of the paionin-1 peptide demanded the addition of DMSO to solubilise the Figure 6C ). Furthermore, we found that biotin-paionin-1 showed decreased binding to latent forms of the variants PAI-1(R78E), PAI-1(R117E/R120E), and PAI-1(K71A/R78A/Y81A/K82A). In contrast, biotin-paionin-1 binding to latent PAI-1 was not affected by the triple mutation R103A/M112A/Q125A, which reduces the apparent affinity for vitronectin more than 3,000-fold [51] ( Figure 6C ). The binding of paionin-1 to active and uPA-complexed PAI-1(R78E), PAI-1(R117E/R120E), and PAI-1(K71A/R78A/Y81A/K82A) was tested in an ELISA similar to the one depicted in Figure 6A and no binding was detected (data not shown).
We finally tested the recombinant variants in their latent form for biotin-paionin-1 binding by SPR analysis ( Figure 6D ). For these experiments, biotin-paionin-1 with a Gly-AlaLys-Lys extension on the C-terminus was immobilised on the sensor chip by amide coupling and used in SPR binding experiments. The obtained sensorgrams were in agreement with the ELISA data as an impaired binding of PAI-1(R78E), PAI-1(R117E/R120E), and PAI-1(K71A/R78A/Y81A/K82A) was evident ( Figure 6D ). Using the same SPR setup, no binding
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between biotin-paionin-1 and the serpins antithrombin III and α 1 -proteinase inhibitor could be detected. In agreement with this, no binding site for paionin-1 in the flexible joint region of these serpins could be identified by an in silico cavity search (data not shown).
The charge-reversing mutations in PAI-1(R78E/R117E/R120E), located in hD (Arg78), hE (Arg117) and the hE/s1A loop (Arg120), were previously reported to impair binding to the PAI-1-neutralizing compounds AR-H029953XX and bis-ANS [12, 13] . XR-5118 was found to have an overlapping, but not identical binding site [13, 49] . Thus, the impaired binding of paionin-1 to variants carrying one or more of these mutations is consistent with paionin-1 binding to this hydrophobic surface area in the flexible joint and in agreement with the competition studies with bis-ANS and XR-5118 (Figure 2A) . Likewise, the decreased binding of paionin-1 to PAI-1(K71A/R78A/Y81A/K82A) and the ability of heparin to compete with paionin-1 for binding ( Figure 2A ) is consistent with Lys71, Arg78 and Lys82 in hD being important for heparin binding [50] . The competition of paionin-1 binding by vitronectin ( Figure 2B ) is readily explainable by steric hindrance from the nearby vitronectin binding site [15, 16] . The impaired binding to murine PAI-1 may result from the replacement of Arg120
with Gln in this ortholog.
In summary, these ELISA and SPR data consistently advocate a binding site for paionin-1 in the flexible joint region of human PAI-1 that becomes more accessible upon the S to R transition. As depicted in Figure 4B , the residues found to be important for paionin-1 binding surround the entrance to the binding cavity proposed from the ligand docking algorithms thus lending support to this analysis.
Paionin-1 and the anti-proteolytic activity of PAI-1
We tested if biotin-paionin-1 was able to affect the activity of PAI-1 towards uPA or to change the rate of latency transition of PAI-1. To this end we employed a chromogenic assay which monitored the activity of uPA in the absence or presence of PAI-1 which had been treated with different concentrations of biotin-paionin-1 for various periods of time. Biotinpaionin-1 did not prevent formation of the uPA-PAI-1 complex but increased the rate of PAI-1 latency transition ~2-fold at concentrations higher than 50 µM, i.e. above the determined CMC (data not shown). This effect is most likely not related to specific peptide-binding but rather a non-specific effect of biotin-paionin-1 aggregates or micelles, analogues to the acceleration of latency transition caused by >100 µM Triton X-100, which has a CMC of 200-300 µM [52] . That biotin-paionin-1 does not impair the activity of PAI-1 though it binds the same area as the PAI-1 neutralisers bis-ANS and XR-5118 exemplifies that the effect of targeting this area depends on the properties of the employed compound. For instance, negatively charged neutralisers including bis-ANS induce PAI-1 polymerisation whereas XR-5118, which carries a positive charge, does not [13, 48, 49] .
Effects of paionin-1 on binding of uPA-PAI-1 complex to VLDLR and LRP-1A
The four alanine substitutions in PAI-1(K71A/R78A/Y81A/K82A), located in the hC/hD-loop (Lys71) and hD (Arg78, Tyr81, and Lys82), reduces the affinity of the uPA-PAI- Monoclonal anti-uPA Mab-2 was included as a control. 
